cagrilintide amylin analog
Selected indexed studies
- Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity. (Cardiol Rev, 2024) [PMID:36883831]
- Development of Cagrilintide, a Long-Acting Amylin Analogue. (J Med Chem, 2021) [PMID:34288673]
- Amylin analogs for the treatment of obesity without diabetes: present and future. (Expert Rev Clin Pharmacol, 2024) [PMID:39317404]
_Worker-drafted node — pending editorial review._
Connections
cagrilintide amylin analog is a side effect of
Sources
- Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity. (2024) pubmed
- Development of Cagrilintide, a Long-Acting Amylin Analogue. (2021) pubmed
- Amylin analogs for the treatment of obesity without diabetes: present and future. (2024) pubmed
- Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. (2023) pubmed
- Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. (2021) pubmed
- Amylin, Another Important Neuroendocrine Hormone for the Treatment of Diabesity. (2024) pubmed
- Drugs for Treating Obesity. (2022) pubmed
- The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines. (2025) pubmed
- Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept. (2025) pubmed
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. (2021) pubmed